- Citi sees good things ahead for Acceleron Pharma (XLRN +2.4%) in 2014, as analyst Yaron Werber reiterates a Buy rating.
- "In 2014 we expect multiple catalysts, extensive partnership with Celgene, and clinical data to continue to drive interest," Werber says, adding that Citi sees "data in both MDS and thalassemia [being] released at ASCO and EHA in June."
- Price target hiked to $50 from $30.
From other sites
at Benzinga.com (Feb 24, 2015)
at Benzinga.com (Dec 31, 2014)
at CNBC.com (Dec 10, 2014)
at Nasdaq.com (Dec 8, 2014)
at CNBC.com (Dec 8, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs